Famciclovir |
Famvir |
Article: Famciclovir
![]() | |
| Famciclovir | |
| Systematic (IUPAC) name | |
| [2-(acetyloxymethyl)-4-(2-aminopurin-9-yl)-butyl] acetate | |
| Identifiers | |
| CAS number | 104227-87-4 |
| ATC code | J05AB09 S01AD07 |
| PubChem | 3324 |
| DrugBank | APRD00600 |
| Chemical data | |
| Formula | C14H19N5O4 |
| Mol. weight | 321.332 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 75–77% |
| Protein binding | 20-25% |
| Metabolism | Hepatic, circulation, intestinal wall (to penciclovir) |
| Half life | 2–2.3 hours |
| Excretion | Renal, faecal |
| Therapeutic considerations | |
| Pregnancy cat. | B1 (Au), B (U.S.) |
| Legal status | S4 (Au), POM (UK), ℞-only (U.S.) |
| Routes | Oral |
Famciclovir (INN) (IPA: [pɛnˈsaɪklovir]) is a guanine analogue antiviral drug used for the treatment of various herpesvirus infections, most commonly for herpes zoster (shingles). It is a prodrug form of penciclovir with improved oral bioavailability. Famciclovir is marketed under the trade name Famvir (Novartis).
See also
- Penciclovir

Not Signed In - 


